RCUS today
$17.77-$1.03 (-5.48%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $31.73
Key levels
Resistance$20.99
Resistance$19.62
Support$17.43
Support$15.09
Latest news & SEC filings
AnalystLeerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49
AnalystTruist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40
All RCUS news →About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company that develops investigational cancer therapies, including combination regimens built around its anti-PD-1 antibody zimberelimab. It collaborates with partners such as Gilead, AstraZeneca, Taiho and Gloria Biosciences on research, development and commercialization of its product candidates. The company relies on contract manufacturers and clinical research organizations and conducts trials in the United States and other countries.
Based on the company's 10-K filed Feb 25, 2026.
NYSE · Healthcare
Arcus Biosciences, Inc. (RCUS)
What Is the Price Target for RCUS?
SEPT Low Target
$26.00
SEPT Mid Target
$44.00
SEPT High Target
$50.00
Analyst Consensus
$44.00
Is RCUS a Buy or Sell Right Now?
Thesis
- •Revenue growing -4.3% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RCUS.
Start Free Trial →Is RCUS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$35.40
13
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with RCUS?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Tang Carolyn C. | officer | Buy | 34,090 | $88K | Jun 11, 2026 |
| Ribas Antoni | director | Buy | 5,700 | - | Jun 11, 2026 |
| Lambert Nicole | director | Buy | 5,700 | - | Jun 11, 2026 |
| Lacey David L. | director | Buy | 5,700 | - | Jun 11, 2026 |
| Machado Patrick | director | Buy | 5,700 | - | Jun 11, 2026 |
| KANEKO YASUNORI | director | Buy | 5,700 | - | Jun 11, 2026 |
| FALBERG KATHRYN E | director | Buy | 5,700 | - | Jun 11, 2026 |
| PERLMAN ANDREW J | director | Buy | 5,700 | - | Jun 11, 2026 |
| Azoy Alexander | officer | Sale | 2,562 | $66K | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RCUS Growth Story
Revenue YoY
-4.3%
3yr Revenue CAGR
30.2%
EPS Growth YoY
-4.78%
FCF Growth YoY
-175.0%
Revenue Trend
STRONG
Dark Pool Trades for RCUS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RCUS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:54 | $17.77 | 2,309 | $$41K | SELL |
| 21:00:54 | $17.77 | 3,224 | $$57K | SELL |
| 21:00:48 | $17.77 | 1,381 | $$25K | SELL |
| 21:00:48 | $17.77 | 2,297 | $$41K | SELL |
| 21:00:48 | $17.77 | 3,213 | $$57K | SELL |
5 dark pool trades shown · $$221K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Arcus Biosciences, Inc. (RCUS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RCUS — frequently asked questions
What is RCUS stock price today?
Arcus Biosciences, Inc. (RCUS) is at $17.77, down 5.48% (-$1.03) at the Nov 12, 2026 close.
Why is RCUS stock moving today?
Latest RCUS news — Nov 5, 2026: Leerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49 · Nov 5, 2026: Truist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40
What is the RCUS price target?
The average analyst price target for RCUS is $44.00, ranging from $26 to $50, based on 10 analysts. Latest: Truist Securities maintains on Nov 5, 2026.
What do analysts rate RCUS?
Analyst ratings for RCUS: 0 Buy, 16 Hold, 0 Sell — consensus Hold.
Did RCUS beat earnings?
RCUS last reported on Nov 4, 2026: EPS -$1.00 vs -$0.89 expected — a miss of 12.3%.
Does RCUS pay a dividend?
RCUS does not currently pay a dividend.
How much debt does RCUS have?
Arcus Biosciences, Inc. reported $101M of debt and $150M of cash (Jun 30, 2026).
What are RCUS support and resistance levels?
Support: $17.43, $15.09, $13.49. Resistance: $19.62, $20.99, $22.80.
What are insiders doing with RCUS?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on RCUS?
Nov 5, 2026: Leerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49 · Nov 5, 2026: Truist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40